The Novel Drugs of 2015 – An Extraordinary Growth of Innovative Pharmaceuticals

DOI:

https://doi.org/10.37285/ijpsn.2016.9.4.1

Authors

  • D. Samba Reddy
  • Savitha Reddy

Abstract

The FDA has approved 45 new drugs in 2015, a record approval in two decades, indicating another year of excellent innovation and productivity. There are many regulatory pathways at the FDA for the approval of novel drugs. Sixteen drugs (36%) were First-in-Class with a new or unique mechanism of action for treating a disease. About 29% of the new drugs are biologics. Moreover, 21 of 45 (47%) are orphan drugs for the treatment of rare diseases. The FDA approved many new drugs to treat various forms of cancer, urinary tract infections, chronic hepatitis C, cystic fibrosis, irritable bowel syndrome, heart failure, and high cholesterol, as well as the first approved reversal agent for a commonly-used blood thinner.  For the second consecutive year, the FDA approved more “orphan” drugs for rare diseases than any previous year in recent history. From 2006 through 2014, the FDA averaged about 28 novel drug approvals per year. Such products represent innovation and provide important new therapies for patients worldwide. Despite such record new drug approvals, there is a continued productivity crisis in R&D due to a progressive rise in cost for drug discovery and development. The U.S. pharmaceutical market is forecasted to reach $548 billion by 2020. The prices appear to be increasing faster for generic and branded prescription drugs. Overall, faster development and regulatory review contributed to a spike in record approval of innovative pharmaceutical products in 2015

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

New dru, NCEs, biologics, fastrack, first-in-class, orphan drugs, block-buster drugs

Downloads

Published

2016-07-31

How to Cite

1.
Reddy DS, Reddy S. The Novel Drugs of 2015 – An Extraordinary Growth of Innovative Pharmaceuticals. Scopus Indexed [Internet]. 2016 Jul. 31 [cited 2024 Nov. 13];9(4):3331-6. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/806

Issue

Section

Review Articles

References

FDA (2016). Novel new drugs 2015 summary. CDER, FDA Brochure, January 2016, pp-1-17.

Jarvis LM (2016). The Year in New Drugs. Chemical & Engineering News 94(5): 12-17.

Reddy DS (2012). Novel new drug approvals in 2011: A succinct analysis of drug discovery trends in the United States. Int J Pharm Sci Nanotech 5(2): 1661-1665.

Reddy DS (2013). New drugs of 2012: A concise overview of the NMEs and trends for innovative brand market in the United States. Int J Pharm Sci Nanotech 6(2): 2009-2013.

Reddy DS (2014). An overview of novel drugs and new chemical entities in 2013. Int J Pharm Sci Nantotech 7(3): 2505-2508.

Reddy SM and Reddy DS (2015). The novel drugs of 2014: Record approvals for niche markets. Int J Pharm Sci Nantotech 8(3): 2889-2893.

Reddy DS and Woodward R (2004). Ganaxolone: A perspective overview. Drugs Future 29: 227-242.

Scannell JW, Blanckley A, Helen Boldon H and Warrington B (2012). Diagnosing the decline in pharmaceutical R & D efficiency. Nature Rev Drug Discovery 11: 191-200.

Mullard A (2016). 2015 FDA drug approvals. Nature Reviews Drug Discovery 15: 73-76.